Nutex Health Inc.
Rank #100HypergrowthNUTX · Nasdaq · Healthcare
Nutex Health Inc. (NUTX) — Rank #100 by gross profitability (GP/assets 0.46) · ROE 18.0% · Piotroski F-Score 7 / 9.
As-of 2026-09-15 · CIK 0001479681 · all metrics point-in-time as of the filing date.
About
Nutex Health Inc. operates as a healthcare services and operations company in the United States.
Show moreShow less
It operates through three segments: Hospital, Population Health Management (PHM), and Real Estate. The Hospital segment develops and operates a network of micro hospitals, specialty hospitals, and hospital outpatient departments that offer healthcare services, including emergency room care, inpatient care, and behavioural health. It also provides imaging services, such as CT scan, X-ray, MRI, ultrasound, etc.; laboratory services; and onsite inpatient pharmacies. The PHM segment provides management, administrative, and other support services to its affiliated hospitals and physician groups by establishing and operating provider networks, such as independent physician associations (IPAs); and a cloud-based technology platform for IPAs. The Real Estate segment owns and leases land and hospital buildings. Nutex Health Inc.
was founded in 2011 and is headquartered in Houston, Texas.
- Industry
- Medical Care Facilities
- Sector
- Healthcare
- State
- DE
- Filer Category
- Accelerated filer
- Fiscal Year End
- December 31
- Website
- nutexhealth.com
Price History
Company Snapshot
P/S is the primary valuation lens — earnings are reinvested, not available for P/E.
Market Cap
$1.45B
P/E (annual)
20.1
P/S (annual)
1.7
P/B
3.7
P/OCF (annual)
5.8
Shareholder Yield
-23.0%
Employees
1,037
Industry
Medical Care Facilities
Exchange
Nasdaq
Signal Flags
Quality Profile
Profitability
1/1 passSafety
1/1 passCash Flow
3/3 passGrowth
1/2 passTerry Smith quality gate
Passes 4/5 Terry Smith thresholds1 of 5 threshold not computable from filed data.
What Growth Is Priced In
Implied revenue growth (10Y)
-9.8%
The annual FCF growth rate today's price requires over a 10-year horizon (discount rate 10%, terminal growth 2.5%).
Dilution drag: 23.0% — per-share value needs a total required return of 13.2% once share-count change is priced in.
vs. own 6-year median revenue growth: 49.2%
within its own historyCost-of-equity sensitivity (implied growth at different discount rates)
r = 8%
-13.0%
r = 10% (base)
-9.8%
r = 12%
-7.0%
Net debt / market cap: -11.6%
Valuation History
Current multiple vs historical range at each filing date. Band spans 25th-75th percentile.
P / S
Price / revenue per share
P / B
Price / book value per share
P / GP
Price / gross profit per share
Disclosure regression check
3 previously-disclosed line items are no longer reported. Worth checking the filing for why.
Revenue growth and the path to profitability (margin trend) are the primary reads at this stage.
Profitability
Gross profitability (GP / assets)
0.46
Primary signal (Novy-Marx).
4th of 9 SIC 7389 peers
Return on equity
18.0%
Gross margin
50.8%
6th of 9 SIC 7389 peers
Revenue growth (YoY)
82.4%
Gross margin improving
Margin trend vs prior year.
Operating Leverage
| 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| Revenue vs COGS | ||||
| Revenue vs OpEx | ||||
| Op. Income vs Revenue |
Growth
Revenue CAGR (3Y)
58.6%
Revenue CAGR (5Y)
26.1%
Earnings CAGR (3Y)
—
FCF CAGR (3Y)
89.7%
Anti-fragile safety
Balance-sheet safety
Composite anti-fragile check.
Debt / equity
0.90
3rd of 7 SIC 7389 peers (best = lowest)
Current ratio
5.00×
2nd of 9 SIC 7389 peers
Quick ratio
2.25×
Net cash
$165.61M
Cash & equivalents minus total debt.
Cash-flow health
Free cash flow
$245.60M
Operating cash flow minus capex.
Positive free cash flow
FCF / net income
2.47
Cash-backing of earnings.
FCF/NI divergence
Unfavorable divergence (yellow flag).
Accruals healthy
Cash-backed earnings.
SBC / revenue
12.3%
Stock-based comp intensity.
Piotroski F-Score
F-Score
7 / 9
Fundamental-strength score (0-9).